| Literature DB >> 36010192 |
Andrea Sambri1, Emilia Caldari1, Michele Fiore1, Claudio Giannini1, Matteo Filippini1, Lorenzo Morante1, Claudia Rondinella1, Eleonora Zamparini2, Sara Tedeschi2,3, Pierluigi Viale2,3, Massimiliano De Paolis1.
Abstract
Prosthetic joint infections (PJIs) occurring in multiple joints at the same time (synchronous PJI) are an extremely rare complication, frequently associated with bacteremia, and are associated with high mortality rates. The presence of three or more prosthetic joints, rheumatoid arthritis, neoplasia, bacteremia and immune-modulating therapy seem to be the recurring risk factors for synchronous PJI. In case of PJIs, all other replaced joints should be considered as potentially infected and investigated if PJI is suspected. Treatments of synchronous multiple PJIs vary and must be decided on a case-by-case basis. However, the advantages of one-stage exchange seem to outweigh the two-stage protocol, as it decreases the number of necessary surgical procedures. Nonetheless, too few studies have been conducted to allow firm conclusions about the best handling of synchronous PJI. Thus, additional studies are needed to understand this devastating complication and to design the most appropriate diagnostic and therapeutic path.Entities:
Keywords: multiple infections; prosthetic joint infection; synchronous infections
Year: 2022 PMID: 36010192 PMCID: PMC9406556 DOI: 10.3390/diagnostics12081841
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1PRISMA ScR algorithm of the included studies.
IHE quality appraisal checklist for case series included in this review.
| Study | Zeller et al. [ | Gausden et al. [ | Thiensen et al. [ | Komnos et al. [ | Abblitt et al. [ |
|---|---|---|---|---|---|
| Q1: was the hypothesis/aim/objective of the study clearly stated? | yes | yes | yes | yes | yes |
| Q2: was the study conducted prospectively? | no | no | no | no | no |
| Q3: were the cases collected in more than one centre? | no | no | no | no | no |
| Q4: were patients recruited consecutively? | yes | yes | yes | yes | yes |
| Q5: were the characteristics of the patients included in the study described? | yes | yes | yes | yes | yes |
| Q6: were the eligibility criteria (i.e., inclusion and exclusion criteria) for entry into the study clearly stated? | yes | yes | yes | yes | yes |
| Q7: did patients enter the study at a similar point in the disease? | yes | yes | yes | yes | yes |
| Q8: was the intervention of interest clearly described? | yes | yes | yes | yes | yes |
| Q9: were additional interventions (co-interventions) clearly described? | no | no | no | no | no |
| Q10: were relevant outcome measures established a priori? | yes | yes | yes | yes | yes |
| Q11: were outcome assessors blinded to the intervention that patients received? | no | no | no | no | no |
| Q12: were the relevant outcomes measured using appropriate objective/subjective methods? | yes | yes | yes | yes | yes |
| Q13: were the relevant outcome measures made before and after the intervention? | no | no | no | no | no |
| Q14: were the statistical tests used to assess the relevant outcomes appropriate? | no | yes | yes | yes | yes |
| Q15: was follow-up long enough for important events and outcomes to occur? | yes | yes | yes | yes | yes |
| Q16: were losses to follow-up reported? | yes | no | no | no | no |
| Q17: did the study provided estimates of random variability in the data analysis of relevant outcomes? | no | yes | yes | yes | no |
| Q18: were the adverse events reported? | yes | yes | yes | no | no |
| Q19: were the conclusions of the study supported by results? | yes | yes | yes | yes | yes |
| Q20: were both competing interests and sources of support for the study reported? | no | no | yes | yes | yes |
| TOTAL (yes/no/unclear) | 12/8/0 | 13/7/0 | 14/6/0 | 13/7/0 | 12/8/0 |
Incidence of synchronous PJIs.
| Study | Patients with Multiple Arthroplasties ( | Synchronous PJI ( | Percent |
|---|---|---|---|
| Zeller et al. [ | 1185 | 16 | 1.4% |
| Gausden et al. [ | 2671 | 34 | 1.3% |
| Thiensen et al. [ | 644 | 26 | 4% |
| Komnos et al. [ | 197 | 11 | 5% |
| Abblitt et al. [ | 76 | 4 | 5% |
Joints involved.
| Study | Joints Involved |
|---|---|
| Zeller et al. [ | 8 bilateral THA, 3 bilateral TKA, 4 TKA and THA, 1 bilateral TKA + THA + toe arthroplasty |
| Gausden et al. [ | 27 bilateral TKA, 3 bilateral THA, 1 TKA + TSA, 1 TKA + TEA, 1 bilateral THA + TKA |
| Thiensen et al. [ | 20 THA, 15 TKA, 7 TSA |
| Komnos et al. [ | 19 THA, 4 TKA |
| Abblitt et al. [ | 3 bilateral TKA, 1 THA + TKA |
Abbreviations: TKA, total knee arthroplasty; THA, total hip arthroplasty; TSA, total shoulder arthroplasty; TEA, total elbow arthroplasty.
Bacteria associated with synchronous PJIs.
| Study | Unknown ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Zeller et al. [ | 8 (50%) | 1 (6%) | 6 (38%) | 1 (6%) | / | / | / | / | / | / |
| Gausden et al. [ | 12 (35%) | 1 (3%) | 4 (12%) | 1 (3%) | 1 (3%) | 1 (3%) | / | 1 (3%) | 1 (3%) | 12 (35%) |
| Thiensen et al. [ | 5 (19.2%) | 9 (34.6%) | 2 (7.7%) | 2 (7.7%) | / | / | 3 (11.5%) | / | / | 4 (11.5%) |
| Komnos et al. [ | 4 (36%) | 3 (27%) | 1 (9%) | 1 (9%) | / | / | / | / | / | 2 (18%) |
| Abblitt et al. [ | 3 (75%) | / | 1 (25%) | / | / | / | / | / | / | / |
Risk factors for synchronous PJI.
| Study | Risk Factors for Synchronous PJI |
|---|---|
| Zeller et al. [ | Staphylococcal or streptococcal bacteremia |
| Gausden et al. [ | Bacteremia |
| Thiensen et al. [ | 3 or more prosthetic joints, rheumatoid arthritis, neoplasia, immune-modulating therapy, bacteremia, sepsis |
| Komnos et al. [ | Bacteremia |
| Abblitt et al. [ | Bacteremia |
| Jafari et al. [ | Immunosuppression |
| Luessenhop et al. [ | Rheumatoid arthritis |
| Haverstock et al. [ | Bacteremia |